Skip to content

Clinical trials

Phase 2 Rare Diseases trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Rare Diseases Phase: Phase 2 Clear all

91 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20012
20061
20131
20141
20151
20162
20171
20191
20201
20222
20232
20241
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed70
Unknown status9
Terminated3
Active, not recruiting3
Recruiting3
Withdrawn1
Not yet recruiting1
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Center for Research Resources (NCRR)39
National Institute of Neurological Disorders and Stroke (NINDS)4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)3
Johns Hopkins University2
National Institute of Allergy and Infectious Diseases (NIAID)2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2
Novartis Pharmaceuticals2
Shionogi2
University of Utah2
Boston University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Rare Diseases91
Genetic Diseases, Inborn14
Mental Disorders14
Neurologic Manifestations14
Communicable Diseases10
Connective Tissue Diseases10
Hematologic Diseases10
Immune System Diseases10
Metabolism, Inborn Errors10
Arthritis9

Trials

Showing 1 to 25 of 91. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.